Oncotelic Therapeutics Inc (OTLC)

$0.09 +0.00 (4.33%)
Market Cap 41.46M
Revenue (ttm) 0.00
Net Income (ttm) -4.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.72
Volume 25,500
Avg Vol 302,014
Day's Range N/A - N/A
Shares Out 441.58M
Stochastic %K 47%
Beta -0.76
Analysts Strong Buy
Price Target $4.00

Company Profile

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatme...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 635 7000
Fax: 650 635 7001
Address:
29397 Agoura Road, Suite 107, Agoura Hills, United States
Ichigodoran
Ichigodoran Dec. 12 at 5:43 PM
Oncotelic $OTLC Investor Information & News https://www.oncotelic.com/corporate-videos/
0 · Reply
Ichigodoran
Ichigodoran Dec. 12 at 5:41 PM
$OTLC Latest News : Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine Oncotelic (OTLC)-owned JV Sapu Nano announced a Deciparticle-led biomarker framework that identifies tumors likely to respond to IV Sapu003, an intravenous everolimus nanomedicine. The analysis evaluated >9,000 patient tumor samples across 20 cancer types and found a High-RICTOR / Low-RPTOR gene-expression signature linked to greater mTOR dependency and predicted sensitivity to IV Sapu003. The signature is enriched in HR+/HER2- breast cancer, lung adenocarcinoma, gastric, renal cell, ovarian, AML and T-cell malignancies. Sapu003 is reported to reduce GI accumulation by 67×, increase tumor tissue penetration, and enable biomarker-driven patient selection. Data will be presented at the 2025 San Antonio Breast Cancer Symposium (Dec 9-12, 2025).
0 · Reply
Ichigodoran
Ichigodoran Dec. 12 at 5:32 PM
$OTLC Watch on Stock Price, News & Analysis https://www.stocktitan.net/overview/OTLC/
0 · Reply
Ichigodoran
Ichigodoran Dec. 11 at 5:07 PM
Oncotelic Therapeutics ($OTLC) Valuation Is Massive is a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments for high-unmet-need cancers and rare pediatric conditions. The company’s pipeline is supported by CEO Dr. Vuong Trieu’s extensive IP portfolio, over 500 patent filings and 75 issued patents, and by strategic partnerships. Oncotelic also owns 45% of GMP Bio, a joint venture advancing complementary drug candidates that strengthen its position in oncology and rare diseases. https://www.youtube.com/watch?v=tgs-nMq9J-E
0 · Reply
Thebullrun
Thebullrun Dec. 11 at 3:50 PM
$OTLC let’s rock n roll!! !!
0 · Reply
Ichigodoran
Ichigodoran Dec. 11 at 2:18 PM
$OTLC From Chemo Medication (Abraxane) to What's Next? Dr. Vuong has billion-dollar Biotech Value visions! https://www.youtube.com/watch?v=-wcvp8FZrBY
0 · Reply
Techallure
Techallure Dec. 11 at 3:46 AM
$OTLC published Dec 10, 2025 Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter by Wen-Han Chang 1,*, Drashya Shah 2, Scott Myers 1, Michael Potts 1, Sanjive Qazi 1 and Vuong Trieu 2ORCID 1 Oncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA 2 Brush and Key Foundation, 4003 Jim Bowie, Agoura Hills, CA 91301, USA * Author to whom correspondence should be addressed. Int. J. Mol. Sci. 2025, 26(24), 11920; https://doi.org/10.3390/ijms262411920 Submission received: 4 October 2025 / Revised: 14 November 2025 / Accepted: 8 December 2025 / Published: 10 December 2025 https://www.mdpi.com/1422-0067/26/24/11920
0 · Reply
Techallure
Techallure Dec. 9 at 8:09 PM
$IBIO Myostatin all part of the TGF-B superfamily …. There is a reason why IBIO will fly just like TGF-B2 gurus behind Oncotelic $OTLC TGF-B and nanomedicine combined with AI The script has been written already Be very prepared as these two TGF concentrated companies have in play Be very prepared …. It is happening
0 · Reply
Ichigodoran
Ichigodoran Dec. 9 at 6:50 PM
$OTLC Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing https://www.otcmarkets.com/stock/OTLC/news/Oncotelic-and-Sapu-Nano-Announces-New-PK-Data-Demonstrating-IV-Sapu003-Reduces-GI-Accumulation-of-Everolimus-up-to-67-Fo?id=502500
0 · Reply
SmallCapGrowth
SmallCapGrowth Dec. 9 at 6:49 PM
Oncotelic Therapeutics $OTLC Valuation - HOT HOT PENNY https://investorshangout.com/post/view?id=6806022
0 · Reply
Latest News on OTLC
No data available.
Ichigodoran
Ichigodoran Dec. 12 at 5:43 PM
Oncotelic $OTLC Investor Information & News https://www.oncotelic.com/corporate-videos/
0 · Reply
Ichigodoran
Ichigodoran Dec. 12 at 5:41 PM
$OTLC Latest News : Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine Oncotelic (OTLC)-owned JV Sapu Nano announced a Deciparticle-led biomarker framework that identifies tumors likely to respond to IV Sapu003, an intravenous everolimus nanomedicine. The analysis evaluated >9,000 patient tumor samples across 20 cancer types and found a High-RICTOR / Low-RPTOR gene-expression signature linked to greater mTOR dependency and predicted sensitivity to IV Sapu003. The signature is enriched in HR+/HER2- breast cancer, lung adenocarcinoma, gastric, renal cell, ovarian, AML and T-cell malignancies. Sapu003 is reported to reduce GI accumulation by 67×, increase tumor tissue penetration, and enable biomarker-driven patient selection. Data will be presented at the 2025 San Antonio Breast Cancer Symposium (Dec 9-12, 2025).
0 · Reply
Ichigodoran
Ichigodoran Dec. 12 at 5:32 PM
$OTLC Watch on Stock Price, News & Analysis https://www.stocktitan.net/overview/OTLC/
0 · Reply
Ichigodoran
Ichigodoran Dec. 11 at 5:07 PM
Oncotelic Therapeutics ($OTLC) Valuation Is Massive is a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments for high-unmet-need cancers and rare pediatric conditions. The company’s pipeline is supported by CEO Dr. Vuong Trieu’s extensive IP portfolio, over 500 patent filings and 75 issued patents, and by strategic partnerships. Oncotelic also owns 45% of GMP Bio, a joint venture advancing complementary drug candidates that strengthen its position in oncology and rare diseases. https://www.youtube.com/watch?v=tgs-nMq9J-E
0 · Reply
Thebullrun
Thebullrun Dec. 11 at 3:50 PM
$OTLC let’s rock n roll!! !!
0 · Reply
Ichigodoran
Ichigodoran Dec. 11 at 2:18 PM
$OTLC From Chemo Medication (Abraxane) to What's Next? Dr. Vuong has billion-dollar Biotech Value visions! https://www.youtube.com/watch?v=-wcvp8FZrBY
0 · Reply
Techallure
Techallure Dec. 11 at 3:46 AM
$OTLC published Dec 10, 2025 Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter by Wen-Han Chang 1,*, Drashya Shah 2, Scott Myers 1, Michael Potts 1, Sanjive Qazi 1 and Vuong Trieu 2ORCID 1 Oncotelic Therapeutics, 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301, USA 2 Brush and Key Foundation, 4003 Jim Bowie, Agoura Hills, CA 91301, USA * Author to whom correspondence should be addressed. Int. J. Mol. Sci. 2025, 26(24), 11920; https://doi.org/10.3390/ijms262411920 Submission received: 4 October 2025 / Revised: 14 November 2025 / Accepted: 8 December 2025 / Published: 10 December 2025 https://www.mdpi.com/1422-0067/26/24/11920
0 · Reply
Techallure
Techallure Dec. 9 at 8:09 PM
$IBIO Myostatin all part of the TGF-B superfamily …. There is a reason why IBIO will fly just like TGF-B2 gurus behind Oncotelic $OTLC TGF-B and nanomedicine combined with AI The script has been written already Be very prepared as these two TGF concentrated companies have in play Be very prepared …. It is happening
0 · Reply
Ichigodoran
Ichigodoran Dec. 9 at 6:50 PM
$OTLC Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing https://www.otcmarkets.com/stock/OTLC/news/Oncotelic-and-Sapu-Nano-Announces-New-PK-Data-Demonstrating-IV-Sapu003-Reduces-GI-Accumulation-of-Everolimus-up-to-67-Fo?id=502500
0 · Reply
SmallCapGrowth
SmallCapGrowth Dec. 9 at 6:49 PM
Oncotelic Therapeutics $OTLC Valuation - HOT HOT PENNY https://investorshangout.com/post/view?id=6806022
0 · Reply
Ichigodoran
Ichigodoran Dec. 9 at 5:58 PM
Oncotelic Therapeutics ($OTLC) Valuation Is Massive https://www.youtube.com/watch?v=tgs-nMq9J-E
0 · Reply
SmallCapGrowth
SmallCapGrowth Dec. 9 at 3:08 PM
Oncotelic Therapeutics Inc (OTLC) ( $OTLC ): Oncotelic Therapeutics $OTLC Valuation I... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177042077 via @Investors_Hub
0 · Reply
Ichigodoran
Ichigodoran Dec. 9 at 2:56 PM
$OTLC looking good ?
0 · Reply
SmallCapGrowth
SmallCapGrowth Dec. 9 at 1:35 PM
Oncotelic Therapeutics $OTLC Valuation Is Massive https://www.youtube.com/watch?v=tgs-nMq9J-E #Stockstobuy #stockstowatch #OTLC #STOCK
0 · Reply
Ichigodoran
Ichigodoran Dec. 9 at 12:57 PM
$OTLC Recent News : Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine https://finance.yahoo.com/news/oncotelic-sapu-nano-announce-deciparticletm-150000503.html
0 · Reply
Thebullrun
Thebullrun Dec. 9 at 12:32 AM
$OTLC
0 · Reply
Ichigodoran
Ichigodoran Dec. 5 at 2:48 PM
$OTLC
0 · Reply
NetworkNewsWire
NetworkNewsWire Dec. 4 at 7:12 PM
InvestorNewsBreaks – $OTLC identifies Biomarker Signature Predicting Sensitivity to IV Sapu003 https://ibn.fm/v99va
0 · Reply
SmallCapGrowth
SmallCapGrowth Dec. 4 at 6:57 PM
#BreakingNews: $OTLC Oncotelic - MOMO'S BREAKOUT BOARD https://investorshangout.com/post/view?id=6805271
0 · Reply
SmallCapGrowth
SmallCapGrowth Dec. 4 at 4:45 PM
#BreakingNews: $OTLC Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine https://www.reddit.com/r/StockInvest/comments/1pe2p8b/otlc_oncotelic_and_sapu_nano_announce/ #Stockstobuy #stockstowatch #OTLC #STOCK
0 · Reply
ckruel
ckruel Dec. 4 at 3:38 PM
$OTLC the call for 2026 is to shift investing into health care, a sector that has been beaten down, as other sectors may suffer in a bearish 2026 market, finally we may see some positive movement in the bio sector.
0 · Reply
SmallCapGrowth
SmallCapGrowth Dec. 4 at 3:19 PM
#BreakingNews: $OTLC Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine https://www.globenewswire.com/news-release/2025/12/04/3199970/0/en/Oncotelic-and-Sapu-Nano-Announce-DeciparticleTM-Led-Biomarker-Framework-Identifying-Tumors-Most-Likely-to-Respond-to-IV-Sapu003-an-Intravenous-Everolimus-Nanomedicine.html #Stockstobuy #stockstowatch #OTLC #STOCK @Charles https://youtube.com/shorts/y3yBcwNvK0s
0 · Reply